ForPatients
by Roche

Glaucoma

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT03293992 BP39863

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase I, multi-center, randomized, adaptive, investigator/patient-masked, placebo-controlled, parallel multiple-ascending dose study (Part A) with an extension including up to two selected doses from Part A and latanoprost 0.005% as active comparator (Part B).

Hoffmann-La Roche Sponsor	**Phase 1** Phase

NCT03293992 BP39863
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 18 Years & <= 90 Years	No